AbbVie Submits Applications for Upadacitinib (RINVOQ®) in Non-Radiographic Axial Spondyloarthritis to U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA)
NORTH CHICAGO, In poor health., Jan. 7, 2022 /PRNewswire/ -- AbbVie (NYSE: ABBV) in the present day introduced that it ...
